🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsPublic SquareNovo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026 Page 4

Novo Nordisk vs Eli Lilly — the GLP-1 market landscape in 2026

anders_CPH Mon, Dec 22, 2025 at 1:00 PM 22 replies 1,194 viewsPage 4 of 5
Dr.GutHealth
Senior Member
1,456
7,890
Mar 2024
Minnesota
Dec 22, 2025 at 6:40 PM#16

Just wanted to say — for anyone reading this Novo Nordisk vs Eli thread who is feeling discouraged: it gets better. The first few weeks are the hardest. Hang in there. 💪

Last edited: Dec 22, 2025 at 11:40 PM
21 15VanRx_Mike, steve_okc, dave_SLC and 18 others
Reply Quote Save Share Report
MounjBrad
Member
278
890
Oct 2024
Kentucky
Dec 22, 2025 at 6:57 PM#17

anders_CPH's experience with Novo Nordisk vs Eli Lilly resonates deeply with mine. I went through almost the identical process — starting dose, titration timeline, side effects, everything.

The main difference: I titrated faster. But the overall trajectory has been remarkably similar. Down 44 lbs in 9 months.

One thing I would add that anders_CPH did not mention: the relationship with food fundamentally changed.

31 1ben_calgary, patPC_UT, Dr.DermMIA and 28 others
Reply Quote Save Share Report
RunnerRach
Member
467
2,123
Aug 2024
Boston, MA
Dec 22, 2025 at 7:14 PM#18

Saving this for reference. Quality thread.

44 9Dr.RaviCardio, jennifer_SEA, tyler_CSCS and 41 others
Reply Quote Save Share Report

PeptideMeter — Independent Peptide Analytics

Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.

View Results
GenomicsKate
Member
345
1,890
Oct 2024
Cambridge, MA
Dec 22, 2025 at 7:31 PM#19

As a healthcare provider, I want to add some clinical context to this discussion on Novo Nordisk vs Eli Lilly the GLP-1.

Building on what anders_CPH said — the evidence base here is well-established. The key publications to reference are from the SURMOUNT program[1].

Key clinical points:

  1. Efficacy is dose-dependent and typically requires 4-5 weeks to reach steady state
  2. Side effect profile is predictable and usually manageable with standard protocols
  3. Monitoring should include baseline labs and follow-up at 3-month intervals
  4. Patient education significantly improves outcomes and adherence

Standard disclaimer: this is educational, not individualized medical advice.

References:
[1] See thread title for relevant study identification.
Last edited: Dec 23, 2025 at 12:31 AM
2 11Dr.PeteFamMed, claudia_zurich
Reply Quote Save Share Report
adam_van
Member
212
890
Nov 2024
Vancouver, CA
Dec 22, 2025 at 7:48 PM#20

Subscribing to this thread. Novo Nordisk vs Eli Lilly is exactly what I've been researching. 🙏

13 2hyun_seoul, jim_asheville, matt_MKE and 10 others
Reply Quote Save Share Report

Similar Threads

SELECT trial 4-year follow-up data released — sustained MACE reduction16 replies
GLP-1 receptor agonists and thyroid C-cell concerns — evidence review19 replies
Is there a ceiling effect for GLP-1-mediated weight loss?20 replies
Comparative pharmacokinetics: semaglutide vs tirzepatide vs retatrutide6 replies
My 18-month semaglutide journey — comprehensive data log20 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register